Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With the SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart

Publication date: Jun 12, 2025

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

Concepts	Keywords
Diabetes	LongCOVID
Immunocompromised	Post-viral conditions
Marijuana
Psychotic

Semantics

Type	Source	Name
disease	MESH	Long COVID
disease	MESH	hypertension
disease	IDO	blood
disease	MESH	fibromyalgia
disease	MESH	interstitial cystitis
disease	MESH	dysautonomia
disease	MESH	SARS-CoV-2 infection
pathway	REACTOME	SARS-CoV-2 Infection
disease	MESH	anemia
disease	MESH	stroke
disease	MESH	cognitive impairment
disease	MESH	depression
disease	MESH	schizophrenia
disease	MESH	delusional disorders
disease	MESH	dementias
disease	IDO	history
disease	MESH	epilepsy
disease	MESH	brain tumor
disease	MESH	multiple sclerosis
disease	MESH	Parkinson’s Disease
disease	MESH	Alzheimer’s disease
disease	MESH	substance abuse
drug	DRUGBANK	Medical Cannabis
disease	MESH	Allergy
drug	DRUGBANK	Histidine
drug	DRUGBANK	Polysorbate 80
drug	DRUGBANK	Ethanol
disease	MESH	chronic infections
disease	MESH	chronic active hepatitis
disease	IDO	immunodeficiency
disease	MESH	renal insufficiency
drug	DRUGBANK	Creatinine
disease	MESH	Liver disease
disease	MESH	hepatic insufficiency
disease	MESH	congestive heart failure
disease	MESH	arrythmia
disease	MESH	ventricular tachycardia
disease	MESH	persistent atrial fibrillation
disease	MESH	heart block
disease	MESH	unstable angina
disease	MESH	myocarditis
disease	MESH	pericarditis
disease	MESH	pulmonary edema
disease	MESH	pulmonary embolism
disease	MESH	dissecting aneurysm
disease	MESH	hypoxemia
disease	MESH	infection
disease	MESH	thyrotoxicosis
disease	MESH	bleeding
disease	MESH	neurologic deficits
disease	MESH	endocrine diseases
disease	MESH	sleep disorders
disease	MESH	sleep deprivation
disease	MESH	hypothyroidism
disease	MESH	chronic Lyme disease
disease	MESH	sequelae
disease	MESH	immunocompromised patients

Original Article

(Visited 1 times, 1 visits today)